Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis

Objectives To compare the ultrasound characteristics with clinical features, final diagnosis and outcome; and to evaluate the halo size following glucocorticoid treatment in patients with newly diagnosed GCA. Methods Patients with suspected GCA, recruited from an international cohort, had an ultrasound of temporal (TA) and axillary (AX) arteries performed within 7 days of commencing glucocorticoids. We compared differences in clinical features at disease presentation, after 2 weeks and after 6 months, according to the presence or absence of halo sign. We undertook a cross-sectional analysis of the differences in halo thickness using Pearson’s correlation coefficient (r) and Analysis of Variance (ANOVA). Results A total of 345 patients with 6 months follow-up data were included; 226 (65.5%) had a diagnosis of GCA. Jaw claudication and visual symptoms were more frequent in patients with halo sign (P =0.018 and P =0.003, respectively). Physical examination abnormalities were significantly associated with the presence of ipsilateral halo (P 0.05). However, the presence of halo at baseline failed to predict future ischaemic events occurring during follow-up. Conclusion In newly diagnosed GCA, TA halo is associated with the presence of ischaemic features and its size decreases following glucocorticoid treatment, supporting its early use as a marker of disease activity, in addition to its diagnostic role

Design, Synthesis And Biological Evaluation Of Hybrid Bioisoster Derivatives Of N-acylhydrazone And Furoxan Groups With Potential And Selective Anti-trypanosoma Cruzi Activity

Hybrid bioisoster derivatives from N-acylhydrazones and furoxan groups were designed with the objective of obtaining at least a dual mechanism of action: cruzain inhibition and nitric oxide (NO) releasing activity. Fifteen designed compounds were synthesized varying the substitution in N-acylhydrazone and in furoxan group as well. They had its anti-Trypanosoma cruzi activity in amastigotes forms, NO releasing potential and inhibitory cruzain activity evaluated. The two most active compounds (6, 14) both in the parasite amastigotes and in the enzyme contain the nitro group in para position of the aromatic ring. The permeability screening in Caco-2 cell and cytotoxicity assay in human cells were performed for those most active compounds and both showed to be less cytotoxic than the reference drug, benznidazole. Compound 6 was the most promising, since besides activity it showed good permeability and selectivity index, higher than the reference drug. Thereby the compound 6 was considered as a possible candidate for additional studies. © 2014 Elsevier Masson SAS. All rights reserved.82418425Coura, J.R., Dias, J.C.P., Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery (2009) Mem. Inst. Oswaldo Cruz, 104, pp. 31-40Anis, R.J., Anis, R., Marin-Neto, J.A., Chagas disease (2010) Lancet, 375, pp. 1388-1402(2013), http://www.who.int/mediacentre/factsheets/fs340/en/index.html, World Health Organization, WHOGascon, J., Bern, C., Pinazo, M.J., Chagas disease in Spain, the United States and other non-endemic countries (2010) Acta Trop., 115, pp. 22-27Nunes, M.C.P., Dones, W., Montillo, C.A., Encina, J.J., Ribeiro, A.L., Chagas disease: An overview of clinical and epidemiological aspects (2013) J. A. Coll. Cardiol., 62, pp. 767-776Dias, L.C., Dessoy, M.A., Silva, J.N.S., Thiemann, O.H., Oliva, G., Andricopulo, A.D., Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos (2009) Quim. Nova, 32, pp. 2444-2457Alves, R.M., Thomaz, R.P., Almeida, E.A., Wanderley, J.S., Guariento, M.E., Chagas disease and egeing: The coexistence of other chronic disease with Chagas disease in elderly patients (2009) Rev. Soc. Bras. Med. Trop., 42, pp. 622-628Barreiro, E.J., Fraga, C.A.M., (2008) Química Medicinal: As Bases Moleculares da Ação Dos Fármacos, pp. 271-277. , second ed. Artmed Porto Alegre 343-345Lima, L.M., Barreiro, E.J., Bioisosterism: A useful strategy for molecular modification and drug design (2005) Curr. Med. Chem., 12, pp. 23-49Viegas-Junior, C., Danuello, A., Bolzani, V.S., Barreiro, E.J., Fraga, C.A.M., Molecular hybridization: A useful tool in the design of new drug prototypes (2007) Curr. Med. Chem., 14, pp. 1829-1852Serafim, R.A.M., Primi, M.C., Trossini, G.H.G., Ferreira, E.I., Nitric oxide: State of the art in drug design (2012) Curr. Med. Chem., 19, pp. 385-405Cerecetto, H., González, M., Anti-T. Cruzi agents: Our experience in the evaluation of more than five hundred compounds (2008) Mini-Rev. Med. Chem., 8, pp. 1355-1383Silva, J.J.N., Guedes, P.M.M., Zottis, A., Balliano, T.L., Silva, F.O.N., Lopes, L.G.F., Ellena, J., Silva, J.S., Novel ruthenium complexesas potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity (2010) Br. J. Pharmacol., 160, pp. 260-269Brunet, L.R., Nitric oxide in parasitic infections (2001) Int. Immunopharmacol., 1, pp. 1457-1467Romeiro, N.C., Aguirre, G., Hernandez, P., Gomzalez, M., Cerecetto, H., Aldana, I., Perez-Silanes, S., Lima, L.M., Synthesis, trypanocidal activity and docking studies of novel quinaxoline-N-acylhydrazones, designed as cruzain inhibitors candidates (2009) Bioorg. Med. Chem., 17, pp. 641-652Moreira, D.R.M., Leite, A.C.L., Santos, R.R., Soares, M.B.P., Approaches for the development of new anti-Trypanosoma cruzi agents (2009) Curr. Drugs Targets, 10, pp. 212-231McGrath, M.E., Eakin, A.E., Engel, J.C., McKerrow, J.H., Craik, C.S., Fletterick, R.J., The crystal structure of cruzain: A therapeutic target for Chagas' disease (1995) J. Mol. Biol., 247, pp. 251-259Judice, W.A.S., Cezari, M.H.S., Lima, A.P.C.A., Scharfstein, J., Chagas, J.R., Tersariol, I.L.S., Juliano, M.A., Juliano, L., Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi (2001) Eur. J. Biochem., 268, pp. 6578-6586Wilkinson, S.R., Bot, C., Kelly, J.M., Hall, B.S., Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives (2011) Curr. Med. Chem., 11, pp. 2072-2084(1998) MarvinView 5.4.0. - Free License, , ChemAxon LtdHernandez, P., Rojas, R., Gilman, R.H., Sauvain, M., Lima, L.M., Barreiro, E.J., Gonzalez, M., Cerecetto, H., Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates (2013) Eur. J. Med. Chem., 59, pp. 64-74Storpirtis, S., Gonçalves, J.E., Chiann, C., Gai, M.N., Biofarmacotécnica-série ciências farmacêuticas (2009) Guanab. Koogan, pp. 204-211Souza, J., Benet, L.Z., Huang, Y., Storpirtis, S., Comparison of bidirectional Lamavudine and Zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers (2009) J. Pharm. Sci., 98, pp. 4413-4419Chavda, H.V., Patel, C.N., Anand, I.S., Biopharmaceutical classification system (2010) Syst. Rev. Pharm., 1, pp. 62-69Huber, P.C., Maruiama, C.H., Almeida, W.P., Glicoproteína-P, resistência a múltiplas drogas (MDR) e relação estrutura-atividade de moduladores (2010) Quim. Nova, 33, pp. 2148-2154Fruttero, R., Ferrarotti, B., Serafino, A., Stiloa, D., Gasco, A., Unsummetrically substituted furoxans, Part 11, methylfuroxancarbaldehydes (1989) J. Heterocycl. Chem., 26, pp. 1345-1347Gasco, A.M., Fruttero, R., Sorba, G., Gasco, A., Unsymmetrically substituted furoxans, Part XIII, phenylfuroxancarbaldehydes and related compounds (1991) Liebigs Ann. Chem., pp. 1211-1213Braman, R.S., Hendrix, S.A., Nanogram nitrite and nitrate determination in enviromental and biological materials by vanadium(III) reduction with chemiluminescence detection (1989) Anal. Chem., 61, pp. 2715-2718Castegnaro, (1978) Food Addit. Contam., 4, pp. 37-43Eakin, A.E., Mills, A.A., Harth, G., McKerrow, J.H., Craik, C.S., The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi (1992) J. Biol. Chem., 267, pp. 7411-7420Li, R., Kenyon, G.L., Cohen, F.E., Chen, X., Gong, B., Dominguez, J.N., Davidson, E., McKerrow, J.H., In vitro antimalarial activity of chacones and their derivatives (1995) J. Med. Chem., 38, pp. 5031-5037Borchardt, D.M., Mascarello, A., Chiaradia, L.D., Nunes, R.J., Oliva, G., Yunes, R.A., Andricopulo, A.D., Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi (2010) J. Braz. Chem. Soc., 21, pp. 142-150Gonçalves, J.E., Fernandes, M.B., Chiann, C., Gai, M.N., Souza, J., Storpirtis, S., Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells (2012) Biopharm. Drug. Dispos., 33, pp. 316-32

Evolution of genes and genomes on the Drosophila phylogeny

Comparative analysis of multiple genomes in a phylogenetic framework dramatically improves the precision and sensitivity of evolutionary inference, producing more robust results than single-genome analyses can provide. The genomes of 12 Drosophila species, ten of which are presented here for the first time (sechellia, simulans, yakuba, erecta, ananassae, persimilis, willistoni, mojavensis, virilis and grimshawi), illustrate how rates and patterns of sequence divergence across taxa can illuminate evolutionary processes on a genomic scale. These genome sequences augment the formidable genetic tools that have made Drosophila melanogaster a pre-eminent model for animal genetics, and will further catalyse fundamental research on mechanisms of development, cell biology, genetics, disease, neurobiology, behaviour, physiology and evolution. Despite remarkable similarities among these Drosophila species, we identified many putatively non-neutral changes in protein-coding genes, non-coding RNA genes, and cis-regulatory regions. These may prove to underlie differences in the ecology and behaviour of these diverse species